放射性^(125)I粒子植入联合支气管动脉灌注化疗治疗晚期肺癌疗效观察

The effect of the ^(125)I seeds implantation in combination with chemotherapeutic drugs through bronchus artery perfusion for advanced lung cancer

目的探讨放射性^(125)I粒子植入联合支气管动脉灌注化疗治疗晚期肺癌的近期疗效及安全性。方法回顾性分析晚期肺癌69例,按入院顺序分为观察组(35例)和对照组(34例),观察组先行放射性^(125)I粒子组织间植入,术前根据TPS计划系统确定^(125)I粒子总活度及粒子分布,术后1周行支气管动脉灌注GP方案化疗4周期。对照组同样先行放射性^(125)I粒子组织间植入,术后1周行GP方案全身静脉化疗4周期,6个月后评价疗效和不良反应。结果观察组有效率为91.43%,对照组有效率为79.41%,两组有效率比较差异有统计学意义(P<0.05);两组患者化疗不良反应发生率比较差异有统计学意义(P<0.01);观察组中位生存期为16个月,对照组为12个月,两组比较差异有统计学意义(P<0.05)。结论放射性^(125)I粒子植入联合支气管动脉灌注化疗治疗晚期肺癌是一种微创、安全、疗效显著、副作用小的治疗方法。

Objective To evaluate the efficacy and safety of the ^(125)I seeds implantation in combination with chemotherapeutic drugs through bronchus artery perfusion for advanced lung cancer. Methods 69 cases with advanced lung cancer were randomly divided into observation group(n=35) and control group(n=34),all the patients were given the ^(125)I seeds implantation,treatment planning system(TPS) was used to calculate total activity and particle distribution of ^(125)I particles before implantation. After one week,the bronchial artery was perfused with GP regimen with 4 cycles of chemotherapy in observation group,and systemic intravenous chemotherapy with GP regimen with 4 cycles were given in control group. Efficacy and adverse reactions were evaluated after 6 months. Results There was statistically significant difference between the effective rate of 91.43% in the observation group and 79.41% in the control group(P<0.05).There was significant difference in the rate of adverse reaction between the two groups(P<0.01). The median overall survival time in the observation group was 16 months and the control group was 12 months,there was significant difference between the two groups(P<0.05). Conclusion The ^(125)I seeds implantation in combination with chemotherapeutic drugs through bronchus artery perfusion for advanced lung cancer is a mini-invasive and safe therapy with remarkable therapeutic results and few side-effects.